Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597057 | 0.95 | PRKCB (1.00) | PRKCBPAK4 | |
| SCHEMBL597936 | 0.93 | PRKCB (1.00) | PRKCB | |
| SCHEMBL597964 | 0.92 | PRKCB (0.88) | PRKCB | |
| SCHEMBL14038609 | 0.89 | PRKCB (1.00) | PRKCB | |
| SCHEMBL598501 | 0.89 | PRKCB (1.00) | PRKCB | |
| SCHEMBL6376847 | 0.86 | PRKCB (0.75) | PRKCBPAK4 | |
| SCHEMBL598000 | 0.84 | PRKCB (1.00) | PRKCB | |
| SCHEMBL597450 | 0.84 | PRKCB (0.91) | PRKCB | |
| SCHEMBL604749 | 0.84 | PRKCB (1.00) | PRKCB | |
| SCHEMBL598183 | 0.84 | PRKCB (1.00) | PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999981-B2 | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives | PFIZER INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20230099852-A1 | TREATMENT OF AUTOIMMUNE DISEASE | MINGSIGHT PHARMACEUTICALS INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220202815-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220202814-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220000870-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401837-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2021-12-30 | — | — | US | disclosed |
| US-11154555-B2 | Treatment of cancer | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3145931-B1 | TREATMENT OF AUTOIMMUNE DISEASE | MINGSIGHT PHARMACEUTICALS INC (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-111568905-A | Treatment of autoimmune diseases | 深圳明赛瑞霖药业有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-106727582-B | Treatment of autoimmune diseases | 深圳明赛瑞霖药业有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-9980965-B2 | Treatment of autoimmune disease | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180098988-A1 | TREATMENT OF AUTOIMMUNE DISEASE | MINGSIGHT PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018013862-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9814716-B2 | Treatment of autoimmune disease | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170196865-A1 | TREATMENT OF AUTOIMMUNE DISEASE | MINGSIGHT PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3145931-A1 | TREATMENT OF AUTOIMMUNE DISEASE | Mingsight Pharmaceuticals, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2195321-B1 | 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C | PFIZER (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015179847-A1 | TREATMENT OF AUTOIMMUNE DISEASE | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8114871-B2 | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives | PFIZER INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100249128-A1 | NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000870-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | PRKCB 4/4885PAK4 264/4885 |
| US-20220202814-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | PRKCB 4/4885PAK4 264/4885 |
| US-20220202815-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | PRKCB 4/4885PAK4 264/4885 |
| US-20210401837-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | PRKCB 4/4885PAK4 264/4885 |
| US-20100249128-A1 | NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, PYCR1 | PRKCB 2011/4885PAK4 3214/4885 |
| US-20180098988-A1 | TREATMENT OF AUTOIMMUNE DISEASE | PRKACB, PRKCH, PRKCE | PRKCB 4/4885PAK4 110/4885 |
| US-20170196865-A1 | TREATMENT OF AUTOIMMUNE DISEASE | PRKACB, PRKCH, PRKCE | PRKCB 4/4885PAK4 110/4885 |
| US-20230099852-A1 | TREATMENT OF AUTOIMMUNE DISEASE | PRKACB, PRKACG, PRKACA | PRKCB 8/4885PAK4 82/4885 |
| US-11154555-B2 | Treatment of cancer | PRKCH, PRKCB, PRKCG | PRKCB 2/4885PAK4 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.